Gland Pharma Ltd
GLANDGland Pharma Ltd
GLANDPrice Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
37.66 | 3.12 | 1.21% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.44 | 6.57 | 0.51% |
Forecast & Ratings
Detailed Forecast from 9 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Gland Pharma is engaged in manufacturing small volume parenterals (SVPs) and contract development services.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 2,772.41 | 3,597.66 | 4,624.65 | 3,865.06 | 5,834.96 | 6,041.87 | ||||||
Raw Materials | 1,108.93 | 1,765.36 | 2,072.53 | 1,732.34 | 2,045.20 | 4,554.23 | ||||||
Power & Fuel Cost | 78.50 | 74.59 | 95.05 | 124.84 | 229.99 | |||||||
Employee Cost | 277.66 | 311.36 | 338.57 | 403.26 | 1,256.89 | |||||||
Selling & Administrative Expenses | 98.54 | 128.48 | 177.92 | 187.93 | 286.86 | |||||||
Operating & Other expenses | 114.15 | -119.14 | 206.49 | 207.92 | 512.71 | |||||||
EBITDA | 1,094.63 | 1,437.01 | 1,734.09 | 1,208.77 | 1,503.31 | 1,487.64 | ||||||
Depreciation/Amortization | 94.59 | 98.78 | 110.30 | 146.74 | 344.57 | 371.21 | ||||||
PBIT | 1,000.04 | 1,338.23 | 1,623.79 | 1,062.03 | 1,158.74 | 1,116.43 | ||||||
Interest & Other Items | 7.18 | 3.41 | 5.24 | 7.45 | 26.20 | 26.91 | ||||||
PBT | 992.86 | 1,334.82 | 1,618.55 | 1,054.58 | 1,132.54 | 1,089.52 | ||||||
Taxes & Other Items | 220.01 | 337.85 | 406.89 | 273.54 | 360.08 | 367.40 | ||||||
Net Income | 772.85 | 996.97 | 1,211.66 | 781.04 | 772.46 | 722.12 | ||||||
EPS | 49.88 | 62.60 | 73.91 | 47.48 | 46.90 | 43.84 | ||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 20.00 | 0.00 | ||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.00 |
Company Updates
Annual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Gland Pharma Ltd | 35.21 | 3.12 | 1.21% |
Sun Pharmaceutical Industries Ltd | 46.31 | 6.61 | 0.73% |
Cipla Ltd | 30.40 | 4.67 | 0.84% |
Torrent Pharmaceuticals Ltd | 65.42 | 15.81 | 0.87% |
Price Comparison
Compare GLAND with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Decreased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has decreased by 2.41%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 2.30%
Top 5 Mutual Funds holding Gland Pharma Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
HDFC Mid-Cap Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 3.6662% | Percentage of the fund’s portfolio invested in the stock 1.28% | Change in the portfolio weight of the stock over the last 3 months -0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 39/79 (-8) |
Mirae Asset Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.4071% | Percentage of the fund’s portfolio invested in the stock 1.63% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 56/104 (-2) |
SBI Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.9150% | Percentage of the fund’s portfolio invested in the stock 1.78% | Change in the portfolio weight of the stock over the last 3 months 0.36% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/88 (+15) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 16, 2024
Dividend/Share
₹20.00
Ex DateEx Date
Aug 16, 2024
Gland Pharma will hold a meeting of the Board of Directors of the Company on 4 November 2024.Powered by Capital Market - Live
Gland Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1809, down 1.76% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.06% on the day, quoting at 25392.05. The Sensex is at 83172.83, up 0.27%.Gland Pharma Ltd has lost around 6.26% in last one month.Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has increased around 2.13% in last one month and is currently quoting at 23025.2, down 0.76% on the day. The volume in the stock stood at 77964 shares today, compared to the daily average of 3.85 lakh shares in last one month.The PE of the stock is 28.14 based on TTM earnings ending June 24.Powered by Capital Market - Live
Gland Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 1936.35, up 1.59% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.02% on the day, quoting at 24856.05. The Sensex is at 81295.07, up 0.14%. Gland Pharma Ltd has slipped around 4.99% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has slipped around 3.48% in last one month and is currently quoting at 23043.4, down 0.28% on the day. The volume in the stock stood at 3.79 lakh shares today, compared to the daily average of 4.18 lakh shares in last one month.The PE of the stock is 29.1 based on TTM earnings ending June 24.Powered by Capital Market - Live
Revenue from operations jumped 15.97% YoY to Rs 1,401.70 crore in Q1 FY25. Profit before tax (PBT) stood at Rs 218.24 crore, down 16.47% as compared with Rs 261.26 crore in Q1 FY24. EBITDA fell to Rs 265.4 crore during the quarter as compared with Rs 298.2 crore in Q1 FY23, registering de-growth of 11%. EBITDA margin reduced from 25% to 19% during the quarter. Revenue from US market stood at Rs 762.8 crore (up 27% YoY), revenue Europe was at Rs 256.6 crore (up 15% YoY), Canada, Australia and New Zealand stood at Rs 44.7 crore (up 72% YoY) while revenue from India was at Rs 52.7 crore (down 19% YoY) and Rest of the world was at Rs 284.9 crore (down 3% YoY) during the period under review. Total capex incurred during the quarter was Rs 63.7 crore. R&D expenses stood at Rs 48.9 crore in Q1 FY25, (5% of revenue). Cenexi's gross profit jumped 24% to Rs 302.6 crore during the quarter as comapred with Rs 243.6 crore in Q1 FY24. Revenue from operations increased 21% YoY to Rs 388.3 crore during the quarter. On outlook front, the company said that In Q2 FY25 Lower activity levels are expected due to the European holiday season and planned summer maintenance shutdowns. The Fontenay plant will have an extended 3-week shutdown for new ampoule line installation. It expects positive EBITDA for Q4 of this fiscal year and a positive EBITDA for the next fiscal year, driven by increased revenue exceeding the '200 million threshold. Srinivas Sadu, executive chairman and CEO of Gland Pharma, said, 'We reached Rs 1,401.7 crore in total revenue, a 16% increase from Q1FY24. This growth aligns with our projections and is primarily driven by the US market, which saw a 27% revenue increase led by existing and certain new products. Our base business EBITDA margins were at 29%, and consolidated EBITDA margins for the quarter were 19%, mainly affected by Cenexi. We're confident in our ability to meet our fiscal year goals and are excited about the growing opportunities and even stronger results expected in the coming quarters.' Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.Powered by Capital Market - Live
Net profit of Gland Pharma declined 25.94% to Rs 143.76 crore in the quarter ended June 2024 as against Rs 194.10 crore during the previous quarter ended June 2023. Sales rose 15.97% to Rs 1401.71 crore in the quarter ended June 2024 as against Rs 1208.69 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1401.711208.69 16 OPM %18.8624.32 - PBDT310.21326.58 -5 PBT218.25261.27 -16 NP143.76194.10 -26 Powered by Capital Market - Live
US FDA issues 3 Form 483 observations to Gland Pharma’s Pashamylaram facility
The said inspection was conducted between 25 July 2024 and 02 August 2024. The said inspection was concluded with three Form 483 Observations. These observations are procedural in nature. The corrective and preventive actions for these observations will be submitted to the US FDA within the stipulated period. The observations issued are neither repeated observations nor related to data integrity,' the company said in a statement. Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. The pharma company reported a consolidated net profit of Rs 192.42 crore in Q4 FY24, steeply higher than Rs 78.68 crore posted in Q4 FY23. Revenue from operations soared 95.85% to Rs 1,537.5 crore during the quarter as against Rs 785.01 crore recorded in Q4 FY23. The scrip fell 2.52% to currently trade at Rs 2074.10 on the BSE. Powered by Capital Market - Live
USFDA issues 3 observations to Gland Pharma Hyderabad Unit, stock down 6%
Stock that will see action today: 5 August 2024
U.S. FDA issues two observations for Gland Pharma facility
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 6.02%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant